Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Insmed has demonstrated the bioequivalence of INS-19, the company's recombinant human granulocyte colony stimulating factor, compared to Neupogen, an FDA-approved G-CSF product for the treatment of neutropenia.
Subscribe to our email newsletter
The clinical study was a single-center, randomized, double-blind, two-way, crossover bioequivalence design in healthy volunteers. Approximately 32 volunteers enrolled and all completed the study as planned.
Each volunteer received a single dose of either INS-19 or Neupogen, underwent a wash-out period, and returned to the clinic for a single dose of the alternate product. Blood samples were collected to characterize the pharmacokinetic and pharmacodynamic responses to each dose administration.
Results of this clinical study demonstrated bioequivalence between INS-19 and Neupogen. Granulocyte colony stimulating factor (G-CSF) concentration profiles for the two products were identical. Absolute neutrophil count, the primary pharmacodynamic marker for G-CSF products, exhibited the same response profile to dosing with INS-19 as with Neupogen.
These human INS-19 and Neupogen data complement Insmed’s extensive analytical testing and comparative data from preclinical assessments.
Geoffrey Allan, president and CEO of Insmed, said: “These results are very exciting, as they represent Insmed’s ability to replicate a protein product, to bring that product rapidly through the clinic and to demonstrate clear bioequivalence to the innovator drug.”